ストックスクリーナーアプリを入手
3.96
2.33%
0.09
アフターアワーズ：
3.95
-0.010
-0.25%
前日終値:
$3.87
開ける：
$3.86
24時間の取引高:
644.58K
Relative Volume:
0.63
時価総額：
$731.53M
収益：
$12.99M
当期純損益:
$-74.39M
株価収益率:
-8.6087
EPS:
-0.46
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
-1.98%
1か月 パフォーマンス:
+3.13%
6か月 パフォーマンス:
+46.13%
1年 パフォーマンス:
+106.25%
1日の値動き範囲:
$3.80
$3.96
1週間の範囲:
$3.80
$4.03
52週間の値動き範囲:
$1.70
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Arbutus Biopharma (ABUS) Set to Announce Earnings on Wednesday - MarketBeat
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Stock: A Year of Declines and Increases - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%Still a Buy? - MarketBeat
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLDThe Liver Meeting® 2024 - Yahoo Finance
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Arbutus Biopharma announces officer retirement terms By Investing.com - Investing.com South Africa
Arbutus Biopharma announces officer retirement terms - Investing.com India
Arbutus Biopharma CSO Michael Sofia Announces Retirement Plans - TipRanks
Examining Arbutus Biopharma Corp (ABUS) stock is warranted - US Post News
Arbutus Biopharma Corp [ABUS] stock for 32,637 USD was sold by MANCHESTER KEITH S - Knox Daily
Balance Sheet Dive: Arbutus Biopharma Corp (ABUS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Top investors say Arbutus Biopharma Corp (ABUS) ticks everything they need - SETE News
XTX Topco Ltd Buys Shares of 17,038 Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Jefferies Upgrades Arbutus Biopharma Corp (ABUS) to a Buy from a Hold - Knox Daily
How to interpret Arbutus Biopharma Corp (ABUS)’s stock chart patterns - US Post News
Taking on analysts’ expectations and winning: Arbutus Biopharma Corp (ABUS) - SETE News
Arbutus Biopharma Corp (ABUS)’s Day in Review: Closing at 3.85, Up by 0.52 - The Dwinnex
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference - Yahoo Finance
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 8.3% in September - MarketBeat
Wall Street SWOT: Arbutus Biopharma stock navigates legal wins and pipeline focus - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 2.8% - MarketBeat
Rhumbline Advisers Purchases 14,607 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
It would be worthwhile to take a closer look at Arbutus Biopharma Corp (ABUS) - US Post News
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? - Yahoo Finance
The growth track for Arbutus Biopharma Corp (ABUS) has changed recently - SETE News
Analyzing Ratios: Arbutus Biopharma Corp (ABUS)’s Financial Story Unveiled - The Dwinnex
Rubric Capital Management LP Invests $5.20 Million in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
ABUS (Arbutus Biopharma) Altman Z-Score : 0.43 (As of Sep. 20, 2024) - GuruFocus.com
Arbutus Biopharma Co. (NASDAQ:ABUS) Stock Position Lifted by Bank of New York Mellon Corp - Defense World
Arbutus Biopharma Corp (ABUS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Arbutus Biopharma Corp (ABUS)’s stock chart: A technical perspective - US Post News
Arbutus Biopharma Corp’s Banking’s 100-Day Moving Average at 3.47: Will the Stock Break Through? - The InvestChronicle
What is Arbutus Biopharma Corp (ABUS) Stock Return on Shareholders’ Capital? - SETE News
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 8.7% in August - Defense World
Principal Financial Group Inc. Lowers Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Metric Analysis: Arbutus Biopharma Corp (ABUS)’s Key Ratios in the Limelight - The Dwinnex
Arbutus Biopharma Corporation (ABUS): Analysts Are Bullish On This Best Debt-Free Penny Stock Now - Insider Monkey
Arbutus Biopharma Corp’s Banking’s 100-Day Moving Average at 3.43: Will the Stock Break Through? - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 3.5% - MarketBeat
What was Arbutus Biopharma Corp (ABUS)’s performance in the last session? - US Post News
Analytical Lens: Exploring Arbutus Biopharma Corp (ABUS)’s Financial Story Through Ratios - The Dwinnex
Biopharma Layoff Tracker 2024: Connect Biopharma, BioMarin and More Cut Staff - BioSpace
Taking the lead: Arbutus Biopharma Corp (ABUS) - SETE News
Arbutus Biopharma (NASDAQ:ABUS) Sets New 12-Month High at $4.56 - MarketBeat
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year? - Yahoo Finance
Market Momentum Report: Arbutus Biopharma Corp (ABUS)’s Positive Close at 4.51 - The Dwinnex
Arbutus Biopharma (NASDAQ:ABUS) Price Target Increased to $7.00 by Analysts at Jefferies Financial Group - Defense World
Arbutus Biopharma (NASDAQ:ABUS) PT Raised to $7.00 - MarketBeat
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
Arbutus Biopharma Corp (ABUS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MANCHESTER KEITH S | Director |
Aug 14 '24 |
Sale |
3.69 |
8,846 |
32,637 |
46,069 |
| Sims Karen | Chief Medical Officer |
Feb 02 '24 |
Sale |
2.31 |
4,358 |
10,078 |
125,542 |
| HASTINGS DAVID C | Chief Financial Officer |
Feb 02 '24 |
Sale |
2.31 |
9,593 |
22,184 |
181,907 |
| Sofia Michael J. | Chief Scientific Officer |
Feb 02 '24 |
Sale |
2.31 |
9,982 |
23,083 |
1,485,121 |
| McElhaugh Michael J. | Interim President & CEO |
Feb 02 '24 |
Sale |
2.31 |
10,164 |
23,504 |
1,504,793 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):